Support is requested to permit the University of Colorado's affiliated hospitals and physicians participation in the scientific efforts of the Southwest Oncology Group. The University is a new member of SWOG. The general objectives are: 1) To bring to SWOG the talents and expertise within the University that will strengthen SWOG's scientific efforts; 2) To maintain scientific and administrative leadership in the areas where we are presently contributing and to additional areas; 3) To develop a number of research proposals, particularly utilizing our strength in the use of biologic agents, monoclonal antibodies and somatic cell genetics, that will be activated by the group; 4) To further strengthen the supporting structure for clinical cancer investigation at the University; 5) To become major patient contributors to the Group's Phase III and multi-modality studies; and 6) To strengthen the University's image as a leading and prudent source of oncologic investigation in the Rocky Mountain area. More specifically, we aim to continue our leadership in the areas of urology and nursing; to supply leadership in the areas of melanoma, monoclonal antibodies, biologic agents, somatic cell cytogenetics, neuro-oncology, urologic pathology, and the pathology and biology of lymphomas.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA042777-01A1
Application #
3558443
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1988-01-01
Project End
1992-12-31
Budget Start
1988-01-01
Budget End
1988-12-31
Support Year
1
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9
Advani, Anjali S; McDonough, Shannon; Copelan, Edward et al. (2014) SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. Br J Haematol 167:233-7

Showing the most recent 10 out of 222 publications